Dr. Emek Blair earned his Bachelor of Science Degree in Chemistry from Occidental College in Los Angeles, Calif. before going on to earn his Doctorate in Chemistry from the University of California, Irvine. Over the past 13 years, Dr. Blair has developed, refined and implemented a proprietary and innovative method for manufacturing custom liposome formulas. Since the development of this method, Dr. Blair has won several awards from the scientific community and has two patents pending.

In 2010, Dr. Blair began formulating and licensing liposomal products to companies.

In early 2015, Dr. Blair founded Valimenta to provide B2B private label manufacturing for custom liposomal products, vitamin supplements, herbal extracts and energy/nutrition drinks. Valimenta uses the proprietary method developed by Dr. Blair which does not require high pressures, high temperatures or toxic synthetic chemicals.

Dr. Blair has formulated upwards of 100 unique liposomal formulas that have successfully been brought to market by some of the largest brands in the world. Several of Dr. Blair’s formulas have been internationally recognized and awarded by the science and supplement industries.

Dr. Blair continues to perform clinical trials with various high-impact medical doctors around the world; this research shows how natural products, when properly delivered, are critical to maximizing health.

Matthew M Halpert earned his B.S. (Biology/Chemistry) with high honors at Southwestern University (Georgetown, TX) from 2002-2006 and then proceeded directly into a doctoral tract at the University of Alabama-Birmingham, where he was a member of the inaugural HHMI-Health to Med Program (with a focus on translating science to the clinic). Dr. Halpert quickly earned his PhD in 2011 from the Department of Microbiology with a focus on Immunology.  Following a brief stint as a postdoctoral fellow at Baylor College of Medicine (Houston, Tx) he accepted a faculty position at BCM, a top medical institution tucked away in the largest medical center in the world (Houston, Tx). Within his research lab over the past decade, the team has focused on studying basic immunological processes, homeostatic regulation, and cancer immunotherapy, the latter of which lead to Dr. Halpert co-founding Diakonos Research Ltd in 2015, an early stage cancer immunotherapy company. With collaborators (e.g. BCM, MD Anderson, Cooper Hospital, Texas Heart Institute, St. Lukes, etc.) Diakonos is on the precipice of numerous FDA-approved phase I clinical trials for the treatment of multiple types of advanced cancer utilizing novel, strong, well-studied science within his lab, as well as several international licensing deals for said science. In addition to his roles with BCM and Diakonos, in 2018 Dr. Halpert accepted a position as the director of R&D for Medterra CBD, and is responsible for the scientific directions of Medterra and of all CBD product related research, development, and innovation.  He currently has over 30 peer reviewed publications, is listed on 9 patents, holds several consulting positions, and has given countless presentations and interviews. In 2020, numerous groups from the NIH solicited his advice and input for ways to improve scientific structures and advancements regarding both ‘cancer cell therapies’ and ‘alternative immune regulators’ such as CBD, and international groups have sought his guidance pertaining to offering cutting-edge cancer immunotherapy to applicable patients in need today.

Previous FDA-approval for cancer clinical trials in the US, and involved in the creation and supervision of international cancer treatment options

Member of inaugural HHMI translational program at UAB, which focused on taking science from the bench to the bedside

Has created custom, patented, scientifically backed synergistic blends for the treatment of multiple disorders and conditions

Has over 30 publications with over 125 citations, and has been invited to speak at numerous national conferences